Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of October 26, 2026, IMRX trades at $3.66 with a market cap of $241.32M and a P/E ratio of -3.22. IMRX moved +0.00% today. Year to date, IMRX is -43.31%; over the trailing twelve months it is -33.75%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $14.00. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immuneering plans Phase 2 trial of atebimetinib plus PD-1 blockade in lung cancer patients: Immuneering said preclinical results showed atebimetinib can strengthen PD-1 checkpoint blockade in RAS-mutant tumor models, supporting a planned Phase 2 lung cancer study. The findings will be presented Nov. 6, 2026, at the SITC annual meeting.
| Metric | Value |
|---|---|
| Price | $3.66 |
| Market Cap | $241.32M |
| P/E Ratio | -3.22 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.08 |
| 52-Week Low | $1.10 |
| Volume | 40.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-56.02M |
| Gross Margin | 0.00% |
4 analysts cover IMRX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.00.